Treatment options for elderly patients in early RRMM: immunomodulatory agents, proteasome inhibitors, anti-CD38 antibodies, and more

Speaker(s)

• 

  Paul G. Richardson, MD

  Clinical Program Leader and Director of Clinical Research
  Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
  Boston, Massachusetts, United States